Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.
Lancet OncolSep 11, 2026 (epub)
Marloes J Hassing, Nicole E Billingy, Corina J G van den Hurk et al.
✦ AI-curated · Sources linked
In 30 seconds
The SYMPRO-Lung trial, a multicentre, stepped-wedged, cluster-randomised clinical trial, evaluated the impact of patient-reported outcome (PRO) symptom monitoring on survival in 446 patients with stage I-IV lung cancer. At a median follow-up of 50 months, the intervention group had a median overall survival of 26 months compared to 21 months in the control group, with a hazard ratio of 0.80 (p=0.049) indicating a potential survival benefit.
Key findings
- Median overall survival was 26 months in the intervention group versus 21 months in the control group.
- PRO symptom monitoring was associated with a hazard ratio of 0.80 for overall survival (95% CI 0.63-1.00, p=0.049).
- No significant difference in progression-free survival was observed between groups (HR 0.86, p=0.18).
- 87% of enrolled patients were included in the post-hoc analysis.
Why it matters
Implementing PRO symptom monitoring in routine care may enhance overall survival outcomes for lung cancer patients, highlighting the importance of integrating patient feedback into clinical practice.